The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

Lantheus is promising up to $1.8 billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tumours (NETs).

In seeking a data-driven approach to efficient drug development, MMS aims to enhance its capabilities in advanced clinical trial design, innovative statistics, and data science with the acquisition.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

At close: April 9 at 4:00:04 PM EDT ...

Real time quote data is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.